Mita Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mita Patel has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Abdo Haddad
Hematology and Oncology, Cleveland Clinic Fairview Hospital, Cleveland, USA
1 shared publication - Bernadette A Clark
Hematology and Oncology, Cleveland Clinic Fairview Hospital, Cleveland, USA
1 shared publication - Bicky Thapa
Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215-5450, USA Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
1 shared publication - Hamed Daw
Hematology and Oncology, Cleveland Clinic Fairview Hospital, Cleveland, USA
1 shared publication - Salome Arobelidze
Internal Medicine, Cleveland Clinic Lerner College of Medicine/Case Western Reserve University (CWRU), Cleveland, USA
1 shared publication - Timothy Pp. Spiro
Department of Hematology and Oncology, Fairview Hospital, Cleveland Clinic, Cleveland, USA
1 shared publication
Latest Publications
- Open Access
- 29 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e28551
Metaplastic Breast Cancer: Characteristics and Survival Outcomes
Metaplastic breast cancer (MBC) is a rare neoplasm accounting for <1% of all breast cancer. We evaluated the clinical characteristics and survival outcomes of MBC. Patients diagnosed with pathologically proven MBC were reviewed from the institutional breast cancer database from 2000 to 2017. A total of 136 patients diagnosed with MBC were included in the study. The median age of the diagnosis was 60 years, and 60% of patients were stage II at diagnosis, and 22% were stage III. About two-thirds of the patients were triple-negative; 93% had nuclear grade III, and 25% had a lymphovascular invasion. Squamous differentiation (29%) was the most common histologic subtype, followed by the spindle subtype (21%). The most common distant metastases were lung (22%), followed by bone (13%). Moreover, 60% had a mastectomy, 19% had endocrine therapy, 58% had radiation, 51% received anthracycline-based chemotherapy, 26% had non-anthracycline chemotherapy, and 22% received no chemotherapy. In the entire cohort, the two-year overall survival (OS) and five-year OS were 79% and 69%, respectively, and the two-year progression-free survival (PFS) and five-year PFS were 72% and 61%, respectively. On multivariable analysis, the stage of MBC (stage III: hazard ratio (HR), 5.065 (95% confidence interval (CI), 1.02-25.27) (p=0.048)), poor functional status (Eastern Cooperative Oncology Group (ECOG) score, 2; HR, 24.736 (95% CI, 1.92-318.73) (p=0.014)), and distant metastasis to the brain (HR, 8.453 (95% CI, 1.88-38.04) (p=0.005)) and lung (HR, 42.102 (95% CI, 7.20-246.36) (p<0.001)) were significant predictors of decreased OS. MBC demonstrated early disease progression and poor overall survival. The stage of MBC, decreased performance status, and metastasis to the lung and brain were independent poor prognostic factors.
- 29 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e28551
Open AccessMetaplastic Breast Cancer: Characteristics and Survival Outcomes
Metaplastic breast cancer (MBC) is a rare neoplasm accounting for <1% of all breast cancer. We evaluated the clinical characteristics and survival outcomes of MBC. Patients diagnosed with pathologically proven MBC were reviewed from the institutional breast cancer database from 2000 to 2017. A total of 136 patients diagnosed with MBC were included in the study. The median age of the diagnosis was 60 years, and 60% of patients were stage II at diagnosis, and 22% were stage III. About two-thirds of the patients were triple-negative; 93% had nuclear grade III, and 25% had a lymphovascular invasion. Squamous differentiation (29%) was the most common histologic subtype, followed by the spindle subtype (21%). The most common distant metastases were lung (22%), followed by bone (13%). Moreover, 60% had a mastectomy, 19% had endocrine therapy, 58% had radiation, 51% received anthracycline-based chemotherapy, 26% had non-anthracycline chemotherapy, and 22% received no chemotherapy. In the entire cohort, the two-year overall survival (OS) and five-year OS were 79% and 69%, respectively, and the two-year progression-free survival (PFS) and five-year PFS were 72% and 61%, respectively. On multivariable analysis, the stage of MBC (stage III: hazard ratio (HR), 5.065 (95% confidence interval (CI), 1.02-25.27) (p=0.048)), poor functional status (Eastern Cooperative Oncology Group (ECOG) score, 2; HR, 24.736 (95% CI, 1.92-318.73) (p=0.014)), and distant metastasis to the brain (HR, 8.453 (95% CI, 1.88-38.04) (p=0.005)) and lung (HR, 42.102 (95% CI, 7.20-246.36) (p<0.001)) were significant predictors of decreased OS. MBC demonstrated early disease progression and poor overall survival. The stage of MBC, decreased performance status, and metastasis to the lung and brain were independent poor prognostic factors.